The University of Chicago Header Logo

Connection

Anjana Pillai to Humans

Back to Details
This is a "connection" page, showing publications Anjana Pillai has written about Humans.
Anjana Pillai
Connection Strength
1.163
Humans
  1. The Changing Demographics and Epidemiology of Hepatocellular Carcinoma. Clin Liver Dis. 2025 Feb; 29(1):1-15.
    View in: PubMed
    Score: 0.032
  2. Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. JAMA. 2024 09 24; 332(12):1013-1014.
    View in: PubMed
    Score: 0.032
  3. Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatol Commun. 2024 06 01; 8(6).
    View in: PubMed
    Score: 0.031
  4. Geographic opportunities for growth in the transplant hepatology training workforce. Liver Transpl. 2024 Oct 01; 30(10):1091-1094.
    View in: PubMed
    Score: 0.031
  5. ACG Clinical Guideline: Focal Liver Lesions. Am J Gastroenterol. 2024 07 01; 119(7):1235-1271.
    View in: PubMed
    Score: 0.030
  6. Contemporary applications of Y90 for the treatment of hepatocellular carcinoma. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.030
  7. Evolving challenges with long-term care of liver transplant recipients. Clin Transplant. 2023 10; 37(10):e15085.
    View in: PubMed
    Score: 0.029
  8. Management of Intermediate-Stage Hepatocellular Carcinoma: Systemic Versus Locoregional Therapy. Surg Oncol Clin N Am. 2024 01; 33(1):159-172.
    View in: PubMed
    Score: 0.029
  9. Many transplant hepatology graduates feel unprepared for first job search: Results from a national employment survey of early career hepatologists. Liver Transpl. 2023 12 01; 29(12):1332-1336.
    View in: PubMed
    Score: 0.029
  10. CAQ Corner: Evaluation and management of living liver donors. Liver Transpl. 2023 10 01; 29(10):1118-1128.
    View in: PubMed
    Score: 0.029
  11. Perspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology. Hepatobiliary Pancreat Dis Int. 2023 02; 22(1):4-6.
    View in: PubMed
    Score: 0.027
  12. Coagulopathy and hemostasis management in patients undergoing liver transplantation: Defining a dynamic spectrum across phases of care. Liver Transpl. 2022 10; 28(10):1651-1663.
    View in: PubMed
    Score: 0.027
  13. HCC Mortality Trends-In with ALD (and NAFLD) and Out with HCV. Dig Dis Sci. 2022 08; 67(8):3483-3484.
    View in: PubMed
    Score: 0.027
  14. Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Aliment Pharmacol Ther. 2022 02; 55(4):479-480.
    View in: PubMed
    Score: 0.026
  15. The New Era of Liver Transplantation for Cholangiocarcinoma: No Longer Just a 1-Man Show. Liver Transpl. 2022 03; 28(3):355-356.
    View in: PubMed
    Score: 0.026
  16. How to Navigate National Societal Organizations for Leadership Development and Academic Promotion: A Guide for Trainees and Young Faculty. Gastroenterology. 2021 11; 161(5):1361-1365.
    View in: PubMed
    Score: 0.026
  17. Recent Advances in Hepatocellular Carcinoma Treatment. Clin Gastroenterol Hepatol. 2021 10; 19(10):2020-2024.
    View in: PubMed
    Score: 0.025
  18. The effect of COVID-19 on liver transplantation: impact, practice patterns, therapeutics, and next steps. Curr Opin Organ Transplant. 2021 06 01; 26(3):339-345.
    View in: PubMed
    Score: 0.025
  19. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. Am J Gastroenterol. 2020 12; 115(12):1960-1969.
    View in: PubMed
    Score: 0.024
  20. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis. 2020 11; 24(4):681-700.
    View in: PubMed
    Score: 0.024
  21. Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol. 2020 11; 115(11):1733-1736.
    View in: PubMed
    Score: 0.024
  22. Lymphoepithelioma-Like Carcinomas: A Rare Variant of Cholangiocarcinoma. Hepatology. 2020 07; 72(1):353-355.
    View in: PubMed
    Score: 0.024
  23. Positron Emission Tomography With Computed Tomography as a Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma: Ready for Prime Time? Liver Transpl. 2020 06; 26(6):746-747.
    View in: PubMed
    Score: 0.023
  24. Approach to Evaluation of Multiple Liver Lesions-Reply. JAMA. 2019 05 28; 321(20):2031-2032.
    View in: PubMed
    Score: 0.022
  25. Liver Allocation Policies in the USA: Past, Present, and the Future. Dig Dis Sci. 2019 04; 64(4):985-992.
    View in: PubMed
    Score: 0.022
  26. A Patient With an Elevated a-Fetoprotein Level and Liver Masses. JAMA. 2019 Jan 01; 321(1):97-98.
    View in: PubMed
    Score: 0.021
  27. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019 Mar; 13(2):125-137.
    View in: PubMed
    Score: 0.021
  28. Mixed Hepatocellular-Cholangiocarcinoma: Is It Time to Rethink Consideration for Liver Transplantation? Liver Transpl. 2018 10; 24(10):1329-1330.
    View in: PubMed
    Score: 0.021
  29. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017 06; 45(11):1427-1432.
    View in: PubMed
    Score: 0.019
  30. Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy. Am J Gastroenterol. 2016 Dec; 111(12):1854-1856.
    View in: PubMed
    Score: 0.018
  31. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016 Feb; 111(2):250-60.
    View in: PubMed
    Score: 0.017
  32. Indwelling peritoneal catheters in patients with cirrhosis and refractory ascites. Intern Med J. 2015 Oct; 45(10):1026-31.
    View in: PubMed
    Score: 0.017
  33. Management of de novo malignancies after liver transplantation. Transplant Rev (Orlando). 2015 Jan; 29(1):38-41.
    View in: PubMed
    Score: 0.016
  34. Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9):3647-51.
    View in: PubMed
    Score: 0.012
  35. Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis. 2009 Nov; 13(4):689-710.
    View in: PubMed
    Score: 0.011
  36. Overview of immunosuppression in liver transplantation. World J Gastroenterol. 2009 Sep 14; 15(34):4225-33.
    View in: PubMed
    Score: 0.011
  37. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008 Jan 23; (1):CD004611.
    View in: PubMed
    Score: 0.010
  38. Influence of Acuity Circles on Hepatocellular Carcinoma and the Interaction of Gender and Race in Liver Transplantation. Clin Transplant. 2024 Dec; 38(12):e70045.
    View in: PubMed
    Score: 0.008
  39. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. 2024 Sep 01; 10(9):1253-1258.
    View in: PubMed
    Score: 0.008
  40. Considerations in gender-affirming hormone therapy in transgender and gender diverse patients undergoing liver transplantation. Am J Transplant. 2024 Sep; 24(9):1567-1572.
    View in: PubMed
    Score: 0.008
  41. Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi. Hepatology. 2024 08 01; 80(2):488-499.
    View in: PubMed
    Score: 0.008
  42. Management of alcohol-associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities. Liver Transpl. 2024 Aug 01; 30(8):848-861.
    View in: PubMed
    Score: 0.008
  43. Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Jul; 35(7):989-997.e2.
    View in: PubMed
    Score: 0.008
  44. Association between bridging therapy and posttransplant outcomes in patients with HCC within Milan criteria: A systematic review and meta-analysis. Liver Transpl. 2024 Jun 01; 30(6):595-606.
    View in: PubMed
    Score: 0.008
  45. Tumor Size and Watershed Area Correlate with Incomplete Treatment and Tumor Progression after Selective Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2024 May; 35(5):712-721.e3.
    View in: PubMed
    Score: 0.008
  46. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. J Hepatol. 2024 Mar; 80(3):431-442.
    View in: PubMed
    Score: 0.007
  47. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease. Nat Microbiol. 2023 Nov; 8(11):2033-2049.
    View in: PubMed
    Score: 0.007
  48. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024 Apr; 34(4):2374-2383.
    View in: PubMed
    Score: 0.007
  49. Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience. J Vasc Interv Radiol. 2023 11; 34(11):1970-1976.e1.
    View in: PubMed
    Score: 0.007
  50. Advances and innovations in living donor liver transplant techniques, matching and surgical training: Meeting report from the living donor liver transplant consensus conference. Clin Transplant. 2023 07; 37(7):e14968.
    View in: PubMed
    Score: 0.007
  51. Financial, policy, and ethical barriers to the expansion of living donor liver transplant: Meeting report from a living donor liver transplant consensus conference. Clin Transplant. 2023 07; 37(7):e14955.
    View in: PubMed
    Score: 0.007
  52. Living donor liver transplantation: A multi-disciplinary collaboration towards growth, consensus, and a change in culture. Clin Transplant. 2023 07; 37(7):e14953.
    View in: PubMed
    Score: 0.007
  53. A survey of transplant providers regarding attitudes, barriers, and facilitators to living donor liver transplantation in the United States. Clin Transplant. 2023 07; 37(7):e14967.
    View in: PubMed
    Score: 0.007
  54. Living donor liver transplant candidate and donor selection and engagement: Meeting report from the living donor liver transplant consensus conference. Clin Transplant. 2023 07; 37(7):e14954.
    View in: PubMed
    Score: 0.007
  55. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. 2023 03 01; 7(3).
    View in: PubMed
    Score: 0.007
  56. Combined heart-liver transplantation practices survey in North America: Evaluation and organ listing practices. Liver Transpl. 2023 06 01; 29(6):591-597.
    View in: PubMed
    Score: 0.007
  57. Practice patterns of the medical evaluation of living liver donors in the United States. Liver Transpl. 2023 02 01; 29(2):164-171.
    View in: PubMed
    Score: 0.007
  58. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int. 2023 03; 43(3):695-707.
    View in: PubMed
    Score: 0.007
  59. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2023 04; 34(4):702-709.
    View in: PubMed
    Score: 0.007
  60. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
    View in: PubMed
    Score: 0.007
  61. Heterogeneity in Center Practices in Liver Transplantation for Alcohol-Associated Liver Disease in the United States. Am J Gastroenterol. 2022 09 01; 117(9):1530-1535.
    View in: PubMed
    Score: 0.007
  62. Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 10 01; 128(19):3470-3478.
    View in: PubMed
    Score: 0.007
  63. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
    View in: PubMed
    Score: 0.007
  64. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785.
    View in: PubMed
    Score: 0.007
  65. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021 11; 157:140-152.
    View in: PubMed
    Score: 0.006
  66. Mandatory Hepatology Education for Internal Medicine Residents: Long-Term Effects and Implications for Workforce Needs. Hepatol Commun. 2021 11; 5(11):1953-1963.
    View in: PubMed
    Score: 0.006
  67. Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes. Liver Transpl. 2021 07; 27(7):1019-1031.
    View in: PubMed
    Score: 0.006
  68. Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clin Gastroenterol Hepatol. 2022 01; 20(1):204-215.e6.
    View in: PubMed
    Score: 0.006
  69. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021 Mar 01; 94(1119):20200752.
    View in: PubMed
    Score: 0.006
  70. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol. 2022 01; 20(1):183-193.
    View in: PubMed
    Score: 0.006
  71. Liver transplantation for alcoholic hepatitis in the United States: Excellent outcomes with profound temporal and geographic variation in frequency. Am J Transplant. 2021 03; 21(3):1039-1055.
    View in: PubMed
    Score: 0.006
  72. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant. 2020 02; 20(2):333-347.
    View in: PubMed
    Score: 0.006
  73. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 11; 157(5):1253-1263.e2.
    View in: PubMed
    Score: 0.006
  74. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983.
    View in: PubMed
    Score: 0.006
  75. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1.
    View in: PubMed
    Score: 0.005
  76. Liver Transplantation in the Obese Cirrhotic Patient. Transplantation. 2017 10; 101(10):2288-2296.
    View in: PubMed
    Score: 0.005
  77. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. Am J Gastroenterol. 2016 09; 111(9):1297-304.
    View in: PubMed
    Score: 0.004
  78. Obscure Gastrointestinal Bleeding in the Setting of Portal Hypertension. J Clin Gastroenterol. 2016 Jan; 50(1):92-3.
    View in: PubMed
    Score: 0.004
  79. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol. 2015 Jul; 30(7):1167-74.
    View in: PubMed
    Score: 0.004
  80. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis. 2015 Oct 15; 61(8):1304-6.
    View in: PubMed
    Score: 0.004
  81. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015 May; 15(5):1162-72.
    View in: PubMed
    Score: 0.004
  82. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014 Apr; 11(4):e1001624.
    View in: PubMed
    Score: 0.004
  83. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2008 May; 6(5):584-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.